Related Experiment Video
Updated: Jun 28, 2025
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Systematic review of the efficacy and safety of lenvatinib in various solid tumors
Shuai Geng1, Tong Liu2, Nan Wang2
1Department of Pharmacy, Strategic Support Force Medical Center, Beijing, China.
Objective:
The purpose of this study was to investigate the efficacy and safety of lenvatinib in various types of solid tumors.
Method:
By searching PubMed, Web of Science, Cochrane, CNKI, Wanfang and other databases, all the literatures about the comparison of clinical efficacy of lenvatinib in the treatment of various solid tumors. According to the criteria of inclusion and exclusion of literature, two participants screened the literature, collated the data and evaluated the literature. RevMan 5.4 software was used for meta-analysis of the included literatures.
Results:
A total of 12 studies were included, including 5213 patients. Meta-analysis showed that, in terms of efficacy, the risk (HR) of prolonging PFS in the treatment of various solid tumors in the lenvatinib group was 1.91 times that in the control group (HR = 1.91, 95% CI: 1.58-2.31, p < 0.00001), and the risk (HR) of prolonging OS was 1.27 times that in the single targeted drug group (HR = 1.27, 95% CI: 1.15-1.40, p < 0.00001). In terms of safety, the risk of adverse events in the treatment of various solid tumors in the lenvatinib group was higher than that in the control group, especially in Endocrine Toxicities, Renal/Urinary Toxicities, Vascular Toxicities, Musculoskeletal/a Connective Tissue Toxicities and Metabolism/Nutrition Toxicities.
Conclusions:
Lenvatinib in various solid tumors can prolong OS and disease PFS of patients, improve the clinical benefit rate and improve the quality of life of patients. At the same time, there is a certain incidence of adverse events, and symptomatic intervention should be given in clinical medication.
Insights
Lenvatinib shows efficacy in treating solid tumors by extending overall survival (OS) and progression-free survival (PFS). However, patients may experience increased adverse events, requiring careful clinical management.
Area of Science:
- Oncology
- Pharmacology
- Clinical Research
Background:
- Lenvatinib is a multi-targeted tyrosine kinase inhibitor used in cancer therapy.
- Its efficacy and safety profile across diverse solid tumors require comprehensive evaluation.
Purpose of the Study:
- To investigate the efficacy and safety of lenvatinib in various types of solid tumors through a meta-analysis.
Main Methods:
- Systematic literature search across multiple databases (PubMed, Web of Science, etc.).
- Inclusion/exclusion criteria applied, data extracted, and meta-analysis performed using RevMan 5.4 software.
- 12 studies with 5213 patients were included.
Main Results:
- Lenvatinib significantly prolonged progression-free survival (PFS) (HR = 1.91) and overall survival (OS) (HR = 1.27) in solid tumor patients.
- Increased risk of adverse events was observed, particularly endocrine, renal/urinary, vascular, musculoskeletal, and metabolic toxicities.
Conclusions:
- Lenvatinib demonstrates effectiveness in improving OS, PFS, and quality of life for patients with solid tumors.
- Clinical use necessitates vigilant monitoring and management of potential adverse events.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...